kabutan

SUSMED,Inc.(4263) Summary

4263
TSE Growth
SUSMED,Inc.
982
JPY
-47
(-4.57%)
Mar 13, 3:30 pm JST
6.16
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
982.1
Mar 13, 10:38 pm JST
Summary Chart Historical News Financial Result
PER
PBR
4.05
Yield
ー%
Margin Trading Ratio
4.38
Stock Price
Mar 13, 2026
Opening Mar 13, 9:01 am
999 JPY 6.27 USD
Previous Close Mar 12
1,029 JPY 6.47 USD
High Mar 13, 10:56 am
1,231 JPY 7.72 USD
Low Mar 13, 2:13 pm
973 JPY 6.10 USD
Volume
1,328,000
Trading Value
1.37B JPY 8.57M USD
VWAP
1028.31 JPY 6.45 USD
Minimum Trading Value
98,200 JPY 616 USD
Market Cap
0.02T JPY 0.10B USD
Number of Trades
3,904
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Slightly High
1-Year Average
757
1-Year High Jul 29, 2025
12,387
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 251,000 1,078,700 4.30
Feb 27, 2026 224,100 1,147,300 5.12
Feb 20, 2026 223,400 1,205,400 5.40
Feb 13, 2026 162,900 1,160,700 7.13
Feb 6, 2026 164,700 1,188,500 7.22
Company Profile
SUSMED, Inc. develops therapeutic applications for patients and provides systems to streamline pharmaceutical development. The company collaborates with pharmaceutical firms.
Sector
Information & Communication
SUSMED, Inc. focuses on developing therapeutic applications and providing support systems for pharmaceutical development. Their insomnia treatment application has received medical device approval and is preparing for insurance coverage. The company is currently developing multiple therapeutic applications, including an exercise therapy app for breast cancer patients and an ACP provision app. SUSMED, Inc. has developed and offers a general-purpose clinical trial system to improve the efficiency of clinical trials, as well as an AI platform called "Awesome Intelligence" for medical data analysis. The company is also working on implementing a remote clinical trial system utilizing blockchain technology. Additionally, SUSMED, Inc. provides DTx development support services for pharmaceutical companies and research institutions.